Use of real world evidence in health technology assessment

Abstract: In this talk the possible situations in which Real World Evidence (RWE), both comparative and single arm studies, could be included in a Meta-Analysis or Network Meta-Analysis (NMA) will be described and discussed. These include; sparse networks, disconnected networks, multiple outcome networks, and the use of such NMAs in terms of decision making and designing future Randomised Controlled Trials (RCTs). In particular, methods for the allowance of potential biases and selection effects associated with RWE and how these may also be incorporated into NMAs will be discussed. The methods will be illustrated using examples in Multiple Sclerosis and Rheumatoid Arthritis from the IMI GetReal Project, as well as examples on Statin use and subsequent risk of diabetes.